

Synthesis of [^3H]FPL 64176, a Potent Calcium Channel Activator

Christian Foged and Peter Madsen*

Novo Nordisk A/S, Pharmaceuticals Division, Novo Nordisk Park, DK-2760 Måløv,
Denmark.


Summary

Tritium labelled FPL 64176 (**1**, methyl 2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1*H*-pyrrole-3-carboxylate), a potent calcium channel activator with insulinotropic properties was synthesised from the corresponding bromo derivative (**3**) using tritium gas and Pd/C catalyst. (**3**) was in turn prepared from methyl 2,5-dimethylpyrrole-3-carboxylate (**4**) in a one pot procedure. The specific activity of [^3H]FPL 64176 was 38 mCi/mmol and radiochemical purity >98%.

Key words: FPL 64176, tritium, calcium channel activator, insulinotropic.

Introduction:

FPL 64176 (**1**, methyl 2,5-dimethyl-4-[2-(phenylmethyl)benzoyl]-1*H*-pyrrole-3-carboxylate) is a potent activator of the voltage-dependent L-type calcium channel¹. It has been shown to possess higher efficacy and a mechanism and site of action that are distinct from those of (S)-Bay K 8644, a dihydropyridine calcium channel activator^{2,3,4}. FPL 64176 has further been shown to be a potent insulin secretagogue from the insulin secreting βTC3 cell line *via* opening of Ca^{2+} channels, followed by Ca^{2+} -influx with concomitant rise in intracellular calcium concentration⁵. In order to further study the mechanism by which FPL 64176 acts, a radioligand would be useful. We now report the synthesis of [^3H]FPL 64176 (**2**).




R = H	FPL 64176	1
R = ^3H	[^3H]FPL 64176	2
R = Br		3

Discussion:

[^3H]FPL 64176 (**2**) was prepared *via* the bromo intermediate (**3**) using tritium gas. An extremely short synthesis of FPL 64176 has been reported⁶, and this method was adopted - with a slight modification - for the synthesis of the key bromo intermediate, **3**, see scheme.

Methyl 2,5-dimethylpyrrole-3-carboxylate (**4**) was Friedel-Crafts acylated with 2-chloromethylbenzoyl chloride, which had been prepared⁷ from phthalide and dichlorotriphenylphosphorane at 180°C without isolation. The unstable **5** thus formed was arylated with bromobenzene *in situ* to give **3** which was isolated by flash chromatography in 19% overall yield.



Scheme

Tritiation of **3** resulted in **2** with a radiochemical purity >98%. HPLC analysis of the reaction mixture showed that no precursor was left after tritiation, resulting in a high specific activity in the product. HPLC purification was not necessary. The specific activity of 38 Ci/mmol indicates, that tritiation also occurs in other parts of the molecule, probably to a large extent in the benzylic position.

Experimental:

TLC was performed on glass plates coated with silica gel 60 F₂₅₄ (Merck). For flash chromatography⁸ silica gel 60 (40–63 μm) was used. Evaporations were performed under reduced pressure at 40° C. Solvents were dried with and kept over molecular sieves (4Å). Melting points were obtained on a Büchi 535 apparatus, ^1H -NMR spectra were recorded on a Bruker AC 300 MHz spectrometer, with chemical shifts δ measured in ppm downfield from internal standard Me_4Si ($\delta = 0$ ppm). Microanalyses were performed at the mikroanalytical laboratory, Novo Nordisk A/S. Tritiation of **3** was done at Amersham, UK. Determination of total radioactivity was done on a Packard 2000 CA tri-card liquid scintillation analyzer, using 20 ml counting vials and Pico-aqua™ Packard liquid scintillator. HPLC analysis was performed using a Merck HPLC pump L-6200 with a rheodyne injector (20 μl) and a Merck UV-detector L-4000 operating at 254 nm. Separations were accomplished at RT with a C-18 coloumn (250 x 4.6 mm, 5 μm) from Novo Nordisk A/S, using an eluent of methanol and water (85:15). The flow rate was 0.8 ml/min.

Methyl 4-[2-(4-bromophenylmethyl)benzoyl]-2,5-dimethylpyrrole-3-carboxylate, **3.**

2.68 g (20 mmoles) Phthalide and 8.48 g (21 mmoles, 80 %) dichlorotriphenylphosphorane was mixed under argon and heated at 180° C for 4 h. The cooled mixture was dissolved in CH_2Cl_2 (20 ml) and 3.25 g (24 mmoles) AlCl_3 was added followed by a solution of 3.00 g (19.6 mmoles) methyl 2,5-dimethylpyrrole-3-carboxylate⁹ in CH_2Cl_2 . After 15 min 3.25 g (24 mmoles) AlCl_3 was added and after another 10 min 40 ml bromobenzene and 3.25 g (24 mmoles) AlCl_3 . Stirring was continued for 15 min. The reaction was quenched by pouring the mixture into water (200 ml). The aqueous phase was extracted with CH_2Cl_2 (200 ml). The combined organic phases were washed with water (3x150 ml), dried (MgSO_4), filtered and evaporated. The residue (ca. 20 g) was chromatographed over silica gel using CH_2Cl_2 :EtOAc 9:1 as eluent. The fractions containing the desired compound were evaporated and crystallized (MeOH). The product was further purified by boiling in methanol and filtering hot, giving 1.54 g (19 %) *methyl 4-[2-(4-bromophenylmethyl)benzoyl]-2,5-dimethylpyrrole-3-carboxylate*. Mp. 208.9–9.5° C. $R_f = 0.45$ (CH_2Cl_2 : EtOAc 9:1). ^1H -NMR (300 MHz) δ_{H} : 2.06 (3H, s), 2.29 (3H,s), 3.09 (3H, s), 4.09 (2H, s), 7.17–7.24 (3H, m), 7.35 (1H, m), 7.44 (2H, d, $J=8.3$ Hz), 11.5 (1H, bs). Anal.: C, H, N.

**Methyl 2,5-dimethyl-4-[2-(4-[³H]-phenylmethyl)benzoyl]-pyrrole-3-carboxylate,
[³H]FPL 64176, **2****

2 mg (5 μ mol) **3** was dissolved in dry THF (1 ml). Triethylamine (2 μ l) and the catalyst 10% Pd/C (about 5 mg) was added. The tritiation was run for 1h at room temperature using 5 Ci tritium gas (86 μ mol, specific activity 58 Ci/mmol). After tritiation the catalyst was removed, and the mixture evaporated. The product was dissolved in ethanol and evaporated. This was repeated several times, to remove all labile tritium. **2** was isolated with a radiochemical purity >98% determined by radio-HPLC. The specific activity was 38 Ci/mmol, determined by radio-HPLC using reference standard and UV-detection. HPLC-analysis showed that no precursor was left after tritiation. The yield was 172 mCi (4.5 μ mol).

References and notes:

- 1) A. J. Baxter, J. Dixon, F. Ince, C. N. Manners & S. J. Teague, *J. Med. Chem.* **36**, 2739-44 (1993).
- 2) D. Rampe, B. Anderson, V. Rapien-Pryor, T. Li & R. C. Dage, *J Pharmacol. Exp. Ther.*, **265**, 1125-30 (1993).
- 3) W. Zheng, D. Rampe & D. J. Triggle, *Mol. Pharmacol.*, **40**, 734-41 (1991).
- 4) D. Rampe & A. E. Lacerda, *J Pharmacol. Exp. Ther.*, **259**, 982-7 (1991).
- 5) J. Springborg, J. Gromada, P. Madsen, A.R. Varming & J. Fuhlendorff, Data presented at 1st. International Meeting of the Pancreatic Islet Study Group, november 25th - 28th at University of Alicanate, Spain.
- 6) C. R. Dalton, J. M. Kane & D. Rampe, *Tetrahedron Lett.*, **33**, 5713-6 (1992).
- 7) D.J. Burton & W.M. Koppes, *J. Org. Chem.*, **40**, 3026-32 (1975).
- 8) W. C. Still, M. Kahn & A. Mitra, *J. Org. Chem.*, **43**, 2923-5 (1978).
- 9) Methyl 2,5-dimethylpyrrole-3-carboxylate was prepared essentially as described by Alexander and Baldwin for the ethyl ester, using methyl acetoacetate, chloroacetone and gaseous ammonia in 39% yield, mp. 119-21° C from ethanol:water 1:2. E.R. Alexander & S. Baldwin, *J. Am. Chem. Soc.*, **73**, 356-8 (1951).